相关实验视频

Updated: Jun 20, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

不同的CEBPA突变对急性髓性白血病治疗结果的影响

Yu Zhao^1,2, Yun Huang¹, Ling Jiang¹

¹Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.

Annals of hematology

|July 17, 2024

概括

在急性髓性白血病 (AML) 中双性CEBPA突变通常会产生良好的预后. 然而,单基CEBPA突变,特别是CEBPA^smTAD,与AML患者的生存结果较差有关.

科学领域:

血液学血液学血液学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

双CEBPA突变 (CEBPA^bi) 通常表明急性髓性白血病 (AML) 的预后有利.
单基CEBPA突变,特别是碳氧终端DNA结合区域 (CEBPAsmbZIP) 和氨基终端交换活化域 (CEBPAsmTAD),呈现出不同的临床特征和治疗反应.
需要进一步的研究,以充分阐明在AML中不同CEBPA突变类型的预后影响.

研究的目的:

为了比较不同类型的CEBPA突变的AML患者的临床特征和生存结果.
研究共突变和全源造血干细胞移植 (allo-HSCT) 对CEBPA突变AML的预后的影响.

主要方法:

77名具有CEBPA突变的AML患者的回顾性分析.
将它们分为三个组:CEBPA^bi (n=53),CEBPA^smbZIP (n=12),以及CEBPA^smTAD (n=12).它们可以分为三个组.
评估临床数据,共变异,对alo-HSCT的反应和最小残留疾病 (MRD3) 状态.

主要成果:

在CEBPA^mut组中观察到年龄,FAB分类,血红蛋白和血小板计数的显著差异.
与CEBPA^bi和CEBPA^smbZIP组相比,CEBPA^smTAD组的2年总生存期 (OS) 和无复发生存期 (RFS) 显著较短.
TET2和GATA2是常见的共同突变,没有显著的预后影响. 在27名患者中,Allo-HSCT改善了RFS. MRD3阳性对OS和RFS产生了负面影响. 艾洛-HSCT对MRD3阳性和不良共变的患者有好处.

结论:

与CEBPA^bi和CEBPA^smbZIP突变相比,CEBPA^smTAD突变与AML的生存率较低有关.
-HSCT可以改善CEBPA突变AML患者的结果,特别是那些MRD3阳性和不良共变的患者.
MRD3状态是CEBPA突变AML的关键预后因素.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.在CEBPA突变中.治疗结果的治疗结果.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...